| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_99505f5f312672820e9f78c254c00a4d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2517-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate |
1998-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcc253f66acf18f0d9e844be0cdb4f38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_add250ee4f88a2463566e4b0dd6d2c9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21a4cbb9691214801bdf0bff98043296
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a07c7ab25ad12c550bea397de8fa8d94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7380275418cb4d3f71e34c9a1cb6a673 |
| publicationDate |
1999-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0917538-A1 |
| titleOfInvention |
Eukaryotic cells expressing at their surface at least an hla-g isoform and their applications |
| abstract |
The invention concerns the use of a eukaryotic cell coding for at least an HLA-G isoform, to obtain an immunomodulating medicine for inhibiting the activity of killer cells, in particular NK cells and/or for inhibiting the primary allogenic response, in pathologies or situations in which the killer cells are activated or for preparing a medicine to raise the inhibiting function of the isoform(s) expressed by said cells with respect to killer cells, in particular NK cells, in pathologies where these killer cells are inhibited by the molecule of the major histocompatibility complex of I HLA-G classes. The invention also concerns eukaryotic cells expressing at their surface at least an HLA-G isoform and their applications. The invention further concerns transgenic animals specifically expressing at least an HLA-G isoform. |
| priorityDate |
1997-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |